Invivyd Soars 10.1% on New Measles Treatment Program

On May 14, 2025, Invivyd's stock surged by 10.1% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Invivyd has recently announced the initiation of a new pipeline discovery program focused on developing a monoclonal antibody treatment for measles. This program aims to address the limitations of current treatment options, which include high-dose Vitamin A and immune globulin (IG). The company's efforts in this area are part of its broader strategy to expand its portfolio of next-generation treatments for infectious diseases.

In addition to the measles program, Invivyd is also advancing its discovery efforts for next-generation COVID-19 treatments and respiratory syncytial virus (RSV) therapies. The company's commitment to innovation in the field of infectious diseases has positioned it as a key player in the biotechnology sector, with a strong focus on developing effective and safe treatments for a range of viral infections.

Invivyd's recent announcements have underscored its dedication to advancing medical science and improving patient outcomes. The company's strategic initiatives and pipeline developments are expected to drive future growth and enhance its market position in the biotechnology industry.